MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03230cam a22003495i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
22288770 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
DE-4047 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20230505163352.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
211028s2022 dcu 000 0 eng |
| 010 ## - LIBRARY OF CONGRESS CONTROL NUMBER |
|---|
| LC control number |
2021949602 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9780309269452 |
| Qualifying information |
(paperback) |
|
|---|
| Canceled/invalid ISBN |
9780309269520 |
| Qualifying information |
(ebook) |
|
|---|
| Canceled/invalid ISBN |
9780309269476 |
| Qualifying information |
(pdf) |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
DLC |
| Language of cataloging |
eng |
| Description conventions |
rda |
| Transcribing agency |
DLC |
| 042 ## - AUTHENTICATION CODE |
|---|
| Authentication code |
pcc |
| 245 00 - TITLE STATEMENT |
|---|
| Title |
Combating antimicrobial resistance and protecting the miracle of modern medicine / |
| Statement of responsibility, etc. |
Committee on the Long-Term Health and Ec. |
| 263 ## - PROJECTED PUBLICATION DATE |
|---|
| Projected publication date |
2201 |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
|---|
| Place of production, publication, distribution, manufacture |
Washington : |
| Name of producer, publisher, distributor, manufacturer |
The National Academies Press, |
| Date of production, publication, distribution, manufacture, or copyright notice |
2022. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
pages cm |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
unmediated |
| Media type code |
n |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
volume |
| Carrier type code |
nc |
| Source |
rdacarrier |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc. |
"The National Academies will convene an expert committee to examine and quantify the long-term medical and economic impacts of increasing antimicrobial resistance (AMR) in the United States. The study shall examine progress made on the U.S. National Strategy and Action Plan for Combating Antibiotic-Resistant Bacteria, including domestic and international strategies employed by NIH, CDC, FDA, ASPR, USDA, and USAID. Opportunities to add to the current body of knowledge include: Advising on an effective strategy to scale up global detection of resistant infections and infection prevention and control efforts-especially outside of the United States and Europe; Helping to assess and quantify the risk to human health from environmental sources and reservoirs of antibiotic-resistant pathogens and genes; Assessing any methodologies for evaluating how interventions in agriculture affect public health and how to improve them; Assessing any methodologies for evaluating the effects of interventions in agricultural settings on animal health and welfare and how to improve them; Assessing the effect of new incentives for antibiotic development (BARDA's project Bioshield, 2019 CMS IPPS) on the health of the antibiotic pipeline; Exploring methodological innovations to improve projections of the burden of AMR and its economic impacts, with an eye toward informing the development of incentives for antimicrobial products; Exploring ways to develop, benchmark, and track rigorous quantitative measures of the effect of various strategies to mitigate AMR, with a focus on relevant, timely, and actionable measures; Assessing the need for and advise on key diseases and antibiotics for which animal-specific antimicrobial susceptibility testing breakpoints are needed; and Assessing the need for and explore how to incentivize and promote cooperative relationships between industry and professional societies to prioritize test development of new diagnostics for use in veterinary settings, especially animal-side diagnostics that allow precise selection of antibiotics"-- |
| Assigning source |
Provided by publisher. |
| 653 ## - INDEX TERM--UNCONTROLLED |
|---|
| Local classification |
Fellow |
|
|---|
| Local classification |
Bayer Fellow in Health & Biotech |
|
|---|
| Local classification |
Class of Spring 2023 |
| 700 1# - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Wilson, Mary E. |
| 9 (RLIN) |
256 |
| 710 2# - ADDED ENTRY--CORPORATE NAME |
|---|
| Corporate name or jurisdiction name as entry element |
Committee on the Long-Term Health and Ec (Washington, District of Columbia), |
| Relator term |
other. |
| 906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) |
|---|
| a |
0 |
| b |
ibc |
| c |
orignew |
| d |
2 |
| e |
epcn |
| f |
20 |
| g |
y-gencatlg |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Source of classification or shelving scheme |
Library of Congress Classification |
| Koha item type |
single unit book |